-
Je něco špatně v tomto záznamu ?
DNA repair capacity and response to treatment of colon cancer
P. Vodicka, S. Vodenkova, T. Buchler, L. Vodickova,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NV15-27580A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
ProQuest Central
od 2000-02-01 do 2020-12-31
Health & Medicine (ProQuest)
od 2000-02-01 do 2020-12-31
PubMed
31691643
DOI
10.2217/pgs-2019-0070
Knihovny.cz E-zdroje
- MeSH
- buněčná smrt účinky léků MeSH
- epigeneze genetická genetika MeSH
- lidé MeSH
- mutace MeSH
- nádory tračníku farmakoterapie genetika patologie MeSH
- nestabilita genomu účinky léků genetika MeSH
- oprava DNA účinky léků MeSH
- poškození DNA účinky léků MeSH
- prognóza MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
DNA repair, a complex biological process, ensures genomic integrity. Alterations in DNA repair, occurring in many cancers, contribute to the accumulation of mutations in the genome, resulting in genomic instability and cancer progression. DNA repair also plays a substantial role in response to chemotherapeutics: rapidly dividing colon cancer cells, vulnerable to DNA-damaging agents and overcoming DNA repair, undergo cell death. DNA repair capacity represents a complex biomarker, integrating gene variants, gene expressions, the stability of gene products, the effect of inhibitors/stimulators, lifestyle and environmental factors. Here, we discuss DNA repair capacity in sporadic colon cancer, a frequent malignancy worldwide, in relation to tumor heterogeneity, prognosis and prediction, measurements in surrogate and target tissues and suggest important tasks to be addressed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025555
- 003
- CZ-PrNML
- 005
- 20201222153948.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/pgs-2019-0070 $2 doi
- 035 __
- $a (PubMed)31691643
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Laboratory of Cancer Treatment and Tissue Regeneration, Faculty of Medicine & Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.
- 245 10
- $a DNA repair capacity and response to treatment of colon cancer / $c P. Vodicka, S. Vodenkova, T. Buchler, L. Vodickova,
- 520 9_
- $a DNA repair, a complex biological process, ensures genomic integrity. Alterations in DNA repair, occurring in many cancers, contribute to the accumulation of mutations in the genome, resulting in genomic instability and cancer progression. DNA repair also plays a substantial role in response to chemotherapeutics: rapidly dividing colon cancer cells, vulnerable to DNA-damaging agents and overcoming DNA repair, undergo cell death. DNA repair capacity represents a complex biomarker, integrating gene variants, gene expressions, the stability of gene products, the effect of inhibitors/stimulators, lifestyle and environmental factors. Here, we discuss DNA repair capacity in sporadic colon cancer, a frequent malignancy worldwide, in relation to tumor heterogeneity, prognosis and prediction, measurements in surrogate and target tissues and suggest important tasks to be addressed.
- 650 _2
- $a buněčná smrt $x účinky léků $7 D016923
- 650 _2
- $a nádory tračníku $x farmakoterapie $x genetika $x patologie $7 D003110
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a oprava DNA $x účinky léků $7 D004260
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a nestabilita genomu $x účinky léků $x genetika $7 D042822
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vodenkova, Sona $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Medical Genetics, Third Faculty of Medicine, Charles University, Ruska 2411/87, 100 00 Prague, Czech Republic.
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University & Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology & Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Laboratory of Cancer Treatment and Tissue Regeneration, Faculty of Medicine & Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 20, č. 17 (2019), s. 1225-1233
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31691643 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153944 $b ABA008
- 999 __
- $a ok $b bmc $g 1599700 $s 1116241
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 17 $d 1225-1233 $e 20191106 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
- GRA __
- $a NV15-27580A $p MZ0
- LZP __
- $a Pubmed-20201125
